Signal Transduction and Targeted Therapy · 2024 · 989 citations · 300 references
Life SciencesCell BiologyMolecular MedicineCellular MetabolismMitochondrial BiologyNeurodegenerationMitochondrial BiochemistryMitochondrial DiseaseMitochondrial DisordersMitochondrial DysfunctionMitochondrial MetabolismMitochondrial PhysiologyHerbal SupplementsMetabolic TherapiesMitochondrial Dysfunction TherapeuticsMitochondrial Function PreservationMitochondrial TargetsMitochondrial TherapyTranslational Clinical Trial Design
Mitochondria, with their intricate networks of functions and information processing, are pivotal in both health regulation and disease progression. Particularly, mitochondrial dysfunctions are identified in many common pathologies, including cardiovascular diseases, neurodegeneration, metabolic syndrome, and cancer. However, the multifaceted nature and elusive phenotypic threshold of mitochondrial dysfunction complicate our understanding of their contributions to diseases. Nonetheless, these complexities do not prevent mitochondria from being among the most important therapeutic targets. In recent years, strategies targeting mitochondrial dysfunction have continuously emerged and transitioned to clinical trials. Advanced intervention such as using healthy mitochondria to replenish or replace damaged mitochondria, has shown promise in preclinical trials of various diseases. Mitochondrial components, including mtDNA, mitochondria-located microRNA, and associated proteins can be potential therapeutic agents to augment mitochondrial function in immunometabolic diseases and tissue injuries. Here, we review current knowledge of mitochondrial pathophysiology in concrete examples of common diseases. We also summarize current strategies to treat mitochondrial dysfunction from the perspective of dietary supplements and targeted therapies, as well as the clinical translational situation of related pharmacology agents. Finally, this review discusses the innovations and potential applications of mitochondrial transplantation as an advanced and promising treatment.
300
Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy
Maj-Linda B. Selenica, Milene L. Brownlow, Jeffy P. Jimenez et al. · Neurodegenerative Diseases · 2012 · 10.4K citations · Full text
Sequence and organization of the human mitochondrial genome
Stephen K. Anderson, Alan T. Bankier, B. G. Barrell et al. · Nature · 1981 · 9.7K citations
Aging: A Theory Based on Free Radical and Radiation Chemistry
Denham Harman · Journal of Gerontology · 1956 · 8.5K citations
Natural Sciences, Chemistry, Aging +16
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Mihael H. Polymeropoulos, Christian Lavedan, Elisabeth Leroy et al. · Science · 1997 · 8.2K citations